JP5184374B2 - 対立遺伝子排除 - Google Patents

対立遺伝子排除 Download PDF

Info

Publication number
JP5184374B2
JP5184374B2 JP2008551908A JP2008551908A JP5184374B2 JP 5184374 B2 JP5184374 B2 JP 5184374B2 JP 2008551908 A JP2008551908 A JP 2008551908A JP 2008551908 A JP2008551908 A JP 2008551908A JP 5184374 B2 JP5184374 B2 JP 5184374B2
Authority
JP
Japan
Prior art keywords
heavy chain
human
locus
antibodies
loci
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2008551908A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009524641A (ja
JP2009524641A5 (cg-RX-API-DMAC7.html
Inventor
グロスヴェルド，フランクリン・ジェラルダス
ヤンセンス，リハルト・ウィルヘルム
クレイグ，ロジャー・キングドン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0601511.9A external-priority patent/GB0601511D0/en
Priority claimed from GBGB0618345.3A external-priority patent/GB0618345D0/en
Application filed by Individual filed Critical Individual
Publication of JP2009524641A publication Critical patent/JP2009524641A/ja
Publication of JP2009524641A5 publication Critical patent/JP2009524641A5/ja
Application granted granted Critical
Publication of JP5184374B2 publication Critical patent/JP5184374B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1009—Picornaviridae, e.g. hepatitis A virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1228—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K16/1232—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia from Escherichia (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1282—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Clostridium (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1285—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Corynebacterium (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/02—Preparation of hybrid cells by fusion of two or more cells, e.g. protoplast fusion
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/01—Animal expressing industrially exogenous proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C12N2015/8518—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic expressing industrially exogenous proteins, e.g. for pharmaceutical use, human insulin, blood factors, immunoglobulins, pseudoparticles

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Environmental Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2008551908A 2006-01-25 2007-01-25 対立遺伝子排除 Active JP5184374B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB0601511.9A GB0601511D0 (en) 2006-01-25 2006-01-25 Binding Molecules 2
GB0601511.9 2006-01-25
GB0618345.3 2006-09-18
GBGB0618345.3A GB0618345D0 (en) 2006-09-18 2006-09-18 Binding molecules
PCT/IB2007/001491 WO2007096779A2 (en) 2006-01-25 2007-01-25 Generation of heavy-chain only antibodies in transgenic animals

Publications (3)

Publication Number Publication Date
JP2009524641A JP2009524641A (ja) 2009-07-02
JP2009524641A5 JP2009524641A5 (cg-RX-API-DMAC7.html) 2010-03-11
JP5184374B2 true JP5184374B2 (ja) 2013-04-17

Family

ID=38437750

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008551908A Active JP5184374B2 (ja) 2006-01-25 2007-01-25 対立遺伝子排除

Country Status (11)

Country Link
US (3) US20090307787A1 (cg-RX-API-DMAC7.html)
EP (1) EP1991580A2 (cg-RX-API-DMAC7.html)
JP (1) JP5184374B2 (cg-RX-API-DMAC7.html)
KR (1) KR101481843B1 (cg-RX-API-DMAC7.html)
AU (1) AU2007219159B8 (cg-RX-API-DMAC7.html)
BR (1) BRPI0706750A2 (cg-RX-API-DMAC7.html)
CA (1) CA2638117A1 (cg-RX-API-DMAC7.html)
RU (1) RU2435784C2 (cg-RX-API-DMAC7.html)
SG (1) SG169348A1 (cg-RX-API-DMAC7.html)
TW (1) TWI404727B (cg-RX-API-DMAC7.html)
WO (1) WO2007096779A2 (cg-RX-API-DMAC7.html)

Families Citing this family (101)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0110029D0 (en) * 2001-04-24 2001-06-13 Grosveld Frank Transgenic animal
ES2440990T5 (es) * 2004-07-22 2022-10-25 Univ Erasmus Med Ct Rotterdam Moléculas de unión
JP5184374B2 (ja) * 2006-01-25 2013-04-17 エラスムス・ユニヴァーシティ・メディカル・センター・ロッテルダム 対立遺伝子排除
SI2602323T1 (en) 2007-06-01 2018-05-31 Open Monoclonal Technology, Inc. Compositions and procedures for inhibiting endogenous immunoglobin gene and the formation of transgenic human idiopathic antibodies
WO2009013620A2 (en) * 2007-06-11 2009-01-29 Erasmus University Medical Center Rotterdam Homologous recombination
EP2288623B1 (en) 2008-05-23 2013-07-10 Ablexis, LLC Method of generating single vl domain antibodies in transgenic animals
US20100122358A1 (en) * 2008-06-06 2010-05-13 Crescendo Biologics Limited H-Chain-only antibodies
RU2011129459A (ru) 2008-12-18 2013-01-27 Эрасмус Юниверсити Медикал Сентр Роттердам Трансгенные животные (не человек), экспрессирующие гуманизированные антитела, и их применение
GB0905023D0 (en) 2009-03-24 2009-05-06 Univ Erasmus Medical Ct Binding molecules
US9445581B2 (en) 2012-03-28 2016-09-20 Kymab Limited Animal models and therapeutic molecules
EP2517556B2 (en) * 2009-07-08 2023-03-22 Kymab Limited Site-Specific Recombination Method, Rodents & Rodent Cells capable of Expressing Chimaeric Antibodies or Chains
DK2509409T3 (en) * 2009-12-10 2016-11-14 Regeneron Pharma MICE, WHICH PRODUCES HEAVY CHAIN ANTIBODIES
US20130045492A1 (en) 2010-02-08 2013-02-21 Regeneron Pharmaceuticals, Inc. Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
US9796788B2 (en) 2010-02-08 2017-10-24 Regeneron Pharmaceuticals, Inc. Mice expressing a limited immunoglobulin light chain repertoire
WO2011097603A1 (en) 2010-02-08 2011-08-11 Regeneron Pharmaceuticals, Inc. Common light chain mouse
RS55495B1 (sr) 2010-08-02 2017-04-28 Regeneron Pharma Miševi koji stvaraju vezujuće proteine koji sadrže vl domene
SI3865581T1 (sl) 2011-08-05 2024-12-31 Regeneron Pharmaceuticals, Inc. Miši s humanizirano univerzalno lahko verigo
CA2846319A1 (en) 2011-09-19 2013-03-28 Kymab Limited Antibodies, variable domains & chains tailored for human use
EP2761008A1 (en) 2011-09-26 2014-08-06 Kymab Limited Chimaeric surrogate light chains (slc) comprising human vpreb
SG10202010120XA (en) 2011-10-17 2020-11-27 Regeneron Pharma Restricted immunoglobulin heavy chain mice
US9253965B2 (en) 2012-03-28 2016-02-09 Kymab Limited Animal models and therapeutic molecules
PL2793567T3 (pl) 2011-12-20 2019-09-30 Regeneron Pharmaceuticals, Inc. Myszy z humanizowanym łańcuchem lekkim
US10251377B2 (en) 2012-03-28 2019-04-09 Kymab Limited Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies
GB2502127A (en) * 2012-05-17 2013-11-20 Kymab Ltd Multivalent antibodies and in vivo methods for their production
CN104540383B (zh) 2012-06-12 2017-08-29 瑞泽恩制药公司 具有受限制的免疫球蛋白重链基因座的人源化非人动物
ES2963516T3 (es) 2012-12-14 2024-03-27 Omniab Inc Polinucleótidos que codifican anticuerpos de roedores con idiotipos humanos y animales que los contienen
WO2014130690A1 (en) 2013-02-20 2014-08-28 Regeneron Pharmaceuticals, Inc. Non-human animals with modified immunoglobulin heavy chain sequences
US9980470B2 (en) 2013-03-14 2018-05-29 Erasmus University Medical Center Antibody production
US10993420B2 (en) 2013-03-15 2021-05-04 Erasmus University Medical Center Production of heavy chain only antibodies in transgenic mammals
US9788534B2 (en) 2013-03-18 2017-10-17 Kymab Limited Animal models and therapeutic molecules
US9783618B2 (en) 2013-05-01 2017-10-10 Kymab Limited Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics
US9783593B2 (en) 2013-05-02 2017-10-10 Kymab Limited Antibodies, variable domains and chains tailored for human use
US11707056B2 (en) 2013-05-02 2023-07-25 Kymab Limited Animals, repertoires and methods
ES2993142T3 (en) 2013-10-01 2024-12-23 Kymab Ltd Animal models and therapeutic molecules
WO2015143406A2 (en) 2014-03-21 2015-09-24 Regeneron Pharmaceuticals, Inc. Vl antigen binding proteins exhibiting distinct binding characteristics
ES2872475T3 (es) 2014-03-21 2021-11-02 Regeneron Pharma Animales no humanos que producen proteínas de unión de dominio único
JP2018508224A (ja) 2015-03-19 2018-03-29 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 抗原を結合する軽鎖可変領域を選択する非ヒト動物
HUE051165T2 (hu) 2015-07-29 2021-03-01 Allergan Inc ANG-2 elleni, csak nehézláncot tartalmazó antitestek
CN105384825B (zh) 2015-08-11 2018-06-01 南京传奇生物科技有限公司 一种基于单域抗体的双特异性嵌合抗原受体及其应用
JP2018523673A (ja) 2015-08-14 2018-08-23 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ Ｐｄｇｆに対する重鎖のみ抗体
WO2017058944A1 (en) 2015-09-29 2017-04-06 Amgen Inc. Asgr inhibitors
WO2018014260A1 (en) 2016-07-20 2018-01-25 Nanjing Legend Biotech Co., Ltd. Multispecific antigen binding proteins and methods of use thereof
WO2018068201A1 (en) 2016-10-11 2018-04-19 Nanjing Legend Biotech Co., Ltd. Single-domain antibodies and variants thereof against ctla-4
EP3332637A1 (en) * 2016-12-09 2018-06-13 Universitätsklinikum Hamburg-Eppendorf Vhh-containing heavy chain antibody and production thereof
CN110662421B (zh) 2017-01-19 2023-03-24 欧莫诺艾比公司 来自具有多个重链免疫球蛋白基因座的转基因啮齿类动物的人抗体
WO2019000223A1 (en) 2017-06-27 2019-01-03 Nanjing Legend Biotech Co., Ltd. ENABLERS OF IMMUNE EFFECTOR CELLS OF CHIMERIC ANTIBODIES AND METHODS OF USE THEREOF
AU2018396964C1 (en) 2017-12-28 2024-10-03 Nanjing Legend Biotech Co., Ltd. Antibodies and variants thereof against PD-L1
AU2018396970B2 (en) 2017-12-28 2025-09-25 Nanjing Legend Biotech Co., Ltd. Single-domain antibodies and variants thereof against TIGIT
CN111699200B (zh) 2018-01-15 2023-05-26 南京传奇生物科技有限公司 针对pd-1的单域抗体和其变体
WO2019175250A1 (en) 2018-03-13 2019-09-19 Smivet B.V. Single domain antibodies binding to tetanus neurotoxin
CN108486125B (zh) * 2018-03-27 2024-01-05 重庆金迈博生物科技有限公司 一种核酸分子及其在制备人源单域抗体中的应用
US11958903B2 (en) 2018-03-30 2024-04-16 Nanjing Legend Biotech Co., Ltd. Single-domain antibodies against LAG-3 and uses thereof
WO2019227490A1 (en) 2018-06-01 2019-12-05 Tayu Huaxia Biotech Medical Group Co., Ltd. Compositions and methods for imaging
JP2021525806A (ja) 2018-06-01 2021-09-27 タユー ファシャ バイオテック メディカル グループ カンパニー， リミテッド 疾患または状態を処置するための組成物およびそれらの使用
US12275788B2 (en) 2018-09-10 2025-04-15 Legend Biotech Ireland Limited Single-domain antibodies against CD33 and constructs thereof
US12263234B2 (en) 2019-01-23 2025-04-01 Tayu Huaxia Biotech Medical Group Co., Ltd. Anti-PD-L1 diabodies and the use thereof
US20220275059A1 (en) 2019-02-20 2022-09-01 Harbour Antibodies Bv Antibodies
MA56120A (fr) 2019-06-07 2022-04-13 Amgen Inc Constructions de liaison bispécifiques
CN110818795B (zh) 2020-01-10 2020-04-24 上海复宏汉霖生物技术股份有限公司 抗tigit抗体和使用方法
EP4097144A4 (en) * 2020-01-28 2024-02-28 University of Southern California Genome engineering the human immunoglobulin locus to express recombinant binding domain molecules
KR20220145859A (ko) 2020-02-28 2022-10-31 상하이 헨리우스 바이오테크, 인크. 항cd137 작제물, 다중 특이적 항체 및 그 용도
BR112022016491A2 (pt) 2020-02-28 2022-10-11 Shanghai Henlius Biotech Inc Construto anti-cd137 e usos do mesmo
GB202003632D0 (en) 2020-03-12 2020-04-29 Harbour Antibodies Bv SARS-Cov-2 (SARS2, COVID-19) antibodies
US20230235075A1 (en) 2020-06-02 2023-07-27 Dynamicure Biotechnology Llc Anti-cd93 constructs and uses thereof
CN116529260A (zh) 2020-06-02 2023-08-01 当康生物技术有限责任公司 抗cd93构建体及其用途
US20230203198A1 (en) 2020-06-04 2023-06-29 Amgen Inc. Bispecific binding constructs
WO2021257679A1 (en) 2020-06-17 2021-12-23 Janssen Biotech, Inc. Materials and methods for the manufacture of pluripotent stem cells
WO2022002038A1 (zh) 2020-06-30 2022-01-06 和铂医药(上海)有限责任公司 免疫细胞衔接器多特异性结合蛋白及其制备和应用
KR20230015996A (ko) 2020-06-30 2023-01-31 하버 바이오메드 (상하이) 컴퍼니 리미티드 H2l2 및 hcab 구조를 갖는 결합 단백질
WO2022011457A1 (en) * 2020-07-13 2022-01-20 Kisoji Biotechnology Inc. Transgenic animals expressing heavy chain antibodies
AU2021315665A1 (en) 2020-07-29 2023-03-16 Dynamicure Biotechnology Llc Anti-CD93 constructs and uses thereof
KR20230062833A (ko) 2020-08-10 2023-05-09 얀센 바이오테크 인코포레이티드 생물공학적 바이러스 특이적 림프구 생산을 위한 재료 및 방법
CN114134144A (zh) * 2020-09-04 2022-03-04 北京仁源欣生生物科技有限公司 一种非人哺乳动物或其子代的制备方法及其应用
CN118126189A (zh) 2020-09-28 2024-06-04 安济盛生物医药有限公司 抗硬骨抑素构建体及其用途
AU2021370895A1 (en) 2020-10-29 2023-06-08 Industrial Polymers and Chemicals, Inc. Air filter with pathogen monitoring and inactivation
GB202017555D0 (en) 2020-11-06 2020-12-23 Harbour Antibodies Bv Antibody-conjugated nanoparticles
CA3203468A1 (en) 2020-12-03 2022-06-09 Amgen Inc. Immunoglobuline constructs with multiple binding domains
US20240023526A1 (en) * 2020-12-09 2024-01-25 Trianni, Inc. Heavy chain-only antibodies
KR102836733B1 (ko) 2021-02-19 2025-07-21 (주)샤페론 Pd-l1 및 cd47에 대한 이중특이적 단일 도메인 항체 및 이의 용도
WO2022177393A1 (ko) 2021-02-19 2022-08-25 (주)샤페론 Pd-l1에 대한 단일 도메인 항체 및 이의 용도
EP4296282A4 (en) 2021-02-19 2025-02-26 SHAPERON Inc. SINGLE DOMAIN ANTIBODIES AGAINST CD47 AND USE THEREOF
EP4301472A1 (en) 2021-03-05 2024-01-10 Dynamicure Biotechnology LLC Anti-vista constructs and uses thereof
JP2024511424A (ja) 2021-03-25 2024-03-13 ダイナミキュア バイオテクノロジー エルエルシー 抗ｉｇｆｂｐ７構築物およびその使用
EP4355785A1 (en) 2021-06-17 2024-04-24 Amberstone Biosciences, Inc. Anti-cd3 constructs and uses thereof
WO2022269473A1 (en) 2021-06-23 2022-12-29 Janssen Biotech, Inc. Materials and methods for hinge regions in functional exogenous receptors
GB202112935D0 (en) 2021-09-10 2021-10-27 Harbour Antibodies Bv Sars-cov-2 (sars2, covid-19) heavy chain only antibodies
WO2023036982A1 (en) 2021-09-10 2023-03-16 Harbour Antibodies Bv Anti-sars2-s antibodies
CN118488965A (zh) 2021-12-17 2024-08-13 上海复宏汉霖生物技术股份有限公司 抗ox40抗体、多特异性抗体及其使用方法
CA3240565A1 (en) 2021-12-17 2023-06-22 Wenfeng Xu Anti-ox40 antibodies and methods of use
AU2023240941A1 (en) 2022-03-25 2024-09-19 Shanghai Henlius Biologics Co., Ltd. Anti-msln antibodies and methods of use
WO2024018426A1 (en) 2022-07-22 2024-01-25 Janssen Biotech, Inc. Enhanced transfer of genetic instructions to effector immune cells
EP4584296A1 (en) 2022-09-07 2025-07-16 Dynamicure Biotechnology LLC Anti-vista constructs and uses thereof
WO2025034806A1 (en) 2023-08-08 2025-02-13 Wisconsin Alumni Research Foundation Single-domain antibodies and variants thereof against fibroblast activation protein
EP4512243A1 (en) * 2023-08-21 2025-02-26 Kymab Limited Binding molecules
WO2025045250A1 (en) 2023-09-03 2025-03-06 Kira Pharmaceuticals (Us) Llc Anti-human factor d antibody constructs and uses thereof
WO2025154058A1 (en) * 2024-01-21 2025-07-24 Ibi-Ag Innovative Bio Insecticides Ltd. Anti-insect hsp70 nanobodies and uses thereof
WO2025178959A1 (en) 2024-02-20 2025-08-28 University Of Georgia Research Foundation, Inc. Single-domain antibodies and variants thereof against tab1
GB202406483D0 (en) 2024-05-09 2024-06-26 Harbour Antibodies Bv Crossing the blood brain barrier to treat diseases of the brain
US20250361309A1 (en) 2024-05-24 2025-11-27 Regeneron Pharmaceuticals, Inc. Tumor-targeted split il12 receptor agonists
WO2025255452A2 (en) 2024-06-07 2025-12-11 Regeneron Pharmaceuticals, Inc. Antigen-binding molecules that bind to aav particles and uses thereof
US20250376524A1 (en) 2024-06-07 2025-12-11 Regeneron Pharmaceuticals, Inc. Tetravalent multispecific binding molecules and methods of use thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4633464A (en) * 1983-08-08 1986-12-30 At&T Bell Laboratories Control signalling arrangement for a digital transmission system
ATE139258T1 (de) 1990-01-12 1996-06-15 Cell Genesys Inc Erzeugung xenogener antikörper
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US7041871B1 (en) 1995-10-10 2006-05-09 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
ATE381614T1 (de) 1992-07-24 2008-01-15 Amgen Fremont Inc Bildung von xenogenen antikörpern
US20050287630A1 (en) * 1995-04-27 2005-12-29 Abgenix, Inc. Human antibodies derived from immunized xenomice
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
EP2305027B1 (en) 1996-12-03 2014-07-02 Amgen Fremont Inc. Transgenic mammals having human Ig loci including plural VH and Vkappa regions and antibodies produced therefrom
EP1311530A4 (en) * 2000-08-03 2004-10-06 Wim-Van Schooten PRODUCTION OF HUMANIZED ANTIBODIES IN TRANSGENIC ANIMALS
GB0110029D0 (en) * 2001-04-24 2001-06-13 Grosveld Frank Transgenic animal
GB0228210D0 (en) * 2002-12-03 2003-01-08 Babraham Inst Single chain antibodies
GB0401882D0 (en) 2004-01-28 2004-03-03 Inpharmatica Ltd Protein
ES2440990T5 (es) * 2004-07-22 2022-10-25 Univ Erasmus Med Ct Rotterdam Moléculas de unión
JP5184374B2 (ja) 2006-01-25 2013-04-17 エラスムス・ユニヴァーシティ・メディカル・センター・ロッテルダム 対立遺伝子排除
US20100122358A1 (en) 2008-06-06 2010-05-13 Crescendo Biologics Limited H-Chain-only antibodies
GB0905023D0 (en) * 2009-03-24 2009-05-06 Univ Erasmus Medical Ct Binding molecules

Also Published As

Publication number Publication date
KR20090013748A (ko) 2009-02-05
SG169348A1 (en) 2011-03-30
US20090307787A1 (en) 2009-12-10
JP2009524641A (ja) 2009-07-02
RU2435784C2 (ru) 2011-12-10
WO2007096779A3 (en) 2008-06-26
US20160295843A1 (en) 2016-10-13
TW200808825A (en) 2008-02-16
WO2007096779A2 (en) 2007-08-30
US20200267951A1 (en) 2020-08-27
AU2007219159B8 (en) 2012-06-28
BRPI0706750A2 (pt) 2011-04-05
AU2007219159A1 (en) 2007-08-30
CA2638117A1 (en) 2007-08-30
EP1991580A2 (en) 2008-11-19
TWI404727B (zh) 2013-08-11
AU2007219159B2 (en) 2012-06-14
RU2008134517A (ru) 2010-02-27
KR101481843B1 (ko) 2015-01-12
US10638735B2 (en) 2020-05-05

Similar Documents

Publication Publication Date Title
JP5184374B2 (ja) 対立遺伝子排除
US11220555B2 (en) Genetic engineering of non-human animals for the production of chimeric antibodies
EP2288623B1 (en) Method of generating single vl domain antibodies in transgenic animals
JP2019068850A (ja) ヒスチジン操作軽鎖抗体およびそれを生成するための遺伝子改変非ヒト動物
KR20110089846A (ko) 키메라 항체의 제조를 위한 인간 이외의 포유동물
JP2010503659A (ja) 結合分子
JP2017537653A (ja) トランスジェニックマウス
CN101410412B (zh) 在转基因动物中产生仅有重链之抗体
MX2008009685A (es) Generacion de anticuerpos solo de cadena pesada en animales transgenicos

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100122

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20100122

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110628

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20110628

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20110628

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120522

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120822

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120829

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20121122

TRDD Decision of grant or rejection written
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20121126

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20121218

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20130116

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

Ref document number: 5184374

Country of ref document: JP

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20160125

Year of fee payment: 3

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250